Fig. 1: RYGB decreases insulin production and maintains euglycemia.
From: Non-insulin determinant pathways maintain glucose homeostasis upon metabolic surgery
a Schematic representation of the RYGB surgery. b Plasma insulin levels in fasting and glucose-stimulated states in RYGB and sham rats (n = 12). c 24 h ambulatory blood glucose levels in sham and RYGB rats (n = 6). d Mean 24-h ambulatory blood glucose levels in sham and RYGB rats (n = 6). e Immunofluorescence staining for insulin and glucagon and HE staining of pancreatic islets in sham and RYGB rats. Scale bar represents 50 μm. f Relative preproinsulin mRNA expression levels in pancreatic tissues from sham and RYGB rats (n = 6). g Plasma proinsulin levels in sham and RYGB rats (n = 7). h Relative Ptbp1 mRNA expression levels in pancreatic tissues from sham and RYGB rats (n = 9). i Immunoblots of PTBP1 in pancreatic tissues from sham and RYGB rats. Quantitative results are shown on the right (n = 6). j Plasma insulin levels in sham and RYGB rats and the AUC values for insulin levels after glucose administration (n = 8). Values are shown as the mean ± s.e.m. Significance was calculated using two-way ANOVA with Tukey’s post hoc analysis (b), two-tailed unpaired t-test (d, e–j), and repeated-measures analysis (j). *P < 0.05 and **P < 0.01 compared with the sham group
